Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran.

Fens T, de Jong L, Kappelhoff B, Boersma C, Postma MJ

Open source

DOI
10.1080/20016689.2023.2247719
Published
2023
Container
Journal of market access & health policy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/20016689.2023.2247719,
  title = {Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran.},
  author = {Fens T and de Jong L and Kappelhoff B and Boersma C and Postma MJ},
  year = {2023},
  journal = {Journal of market access \& health policy},
  doi = {10.1080/20016689.2023.2247719},
  url = {https://doi.org/10.1080/20016689.2023.2247719}
}

RIS

TY  - JOUR
TI  - Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran.
AU  - Fens T
AU  - de Jong L
AU  - Kappelhoff B
AU  - Boersma C
AU  - Postma MJ
PY  - 2023
JO  - Journal of market access & health policy
DO  - 10.1080/20016689.2023.2247719
UR  - https://doi.org/10.1080/20016689.2023.2247719
ER  - 

APA

T, F., L, D. J., B, K., C, B., & MJ, P. (2023). Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran.. Journal of market access & health policy. https://doi.org/10.1080/20016689.2023.2247719

Source records